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We developed a microarray-based system for screening small
molecules in mammalian cells. This system is compatible with
image-based screens and requires fewer than 100 cells per com-
pound. Each compound is impregnated in a 200-m-diameter disc
composed of biodegradable poly-(D),(L)-lactideglycolide copoly-
mer. Cells are seeded on top of these discs, and compounds slowly
diffuse out, affecting proximal cells. In contrast with microtiter-
based screening, this system does not involve the use of wells or
walls between each compound-treated group of cells. We demon-
strate detection of the effects of a single compound in a large
microarray, that diverse compounds can be released in this format,
and that extended release over several days is feasible. We per-
formed a small synthetic lethal screen and identified a compound
(macbecin II) that has reduced activity in cells with RNA interfer-
ence-mediated decrease in the expression of tuberous sclerosis 2.
Thus, we have developed a microarray-based screening system for
testing the effects of small molecules on mammalian cells by using
an imaging-based readout. This method will be useful to those
performing small-molecule screens to discover new chemical tools
and potential therapeutic agents.
M icroarrays are widely used tools in the postgenomic era: Theycan be used to generate a vast amount of data in a short
period with highly parallel experimental methods and analyses
(1–4). Early microarrays consisted of regularly repeating arrays of
DNA (5, 6) and were used to measure changes in gene expression
by converting cellularmRNA to a fluorescently labeled nucleic acid
andhybridizing it to aDNAmicroarray (2). In addition,microarrays
with features containing expression plasmids or small interfering
RNAs (siRNAs) can be used to transfect mammalian cells to study
the consequences of perturbing, in parallel, the expression of a large
number of genes (7–9).
More recently, microarrays have been extended to proteins and
small molecules (4, 10–20). Protein microarrays have been created
for measuring protein activities, interactions between proteins, and
ligand binding to proteins (21–24); smallmoleculemicroarrays have
been used for detecting the interactions between proteins andmany
small molecules (10, 25–29). These previously reported small-
molecule microarrays have been used exclusively to detect in vitro
interactions; it has not been possible to test the effects of small
molecules on cells in a microarray format.
We sought to develop a microarray format for performing
high-throughput screens of small molecules in mammalian cells.
We envisioned that such a technology would be valuable for
chemical genetic screens and for drug discovery efforts. Chem-
ical genetics involves testing thousands of small molecules for
their effects on a cellular or organismal phenotype; subse-
quently, the proteins targeted by these phenotype-modifying
compounds are identified. This process can reveal proteins that
regulate biological processes of interest (30–35).
Here, we describe the creation of microarrays consisting of small
molecules impregnated in a biodegradable polymer and printed on
a standard microscope slide. Amonolayer of cells is grown over the
array, allowing each compound to affect proximal cells. To localize
compounds on a slide surface, we used a biodegradable poly-
(D),(L)-lactideglycolide copolymer (PLGA) after assessing more
than two dozen different polymer materials. It was not clear, a
priori, that any polymer would be useful in a microarray format,
which requires that the polymer matrix exhibit a sufficiently large
barrier to diffusion such that compounds are slowly released from
a flat disc with a volume on the order of 1 nl. The nontoxic and
slow-release properties of PLGA have been documented for a
variety of purposes (36), ranging from the delivery of insulin-like
growth factor for the treatment of osteoporosis (37) to that of
paclitaxel for the treatment of tumors (38). PLGA and other
poly(lactic acid) polymers enable the controlled release of proteins
and small molecules through a combination of drug diffusion and
polymer erosion in the context of large macroscopic amounts of
polymer (36, 39).
By using PLGA as a scaffold, we developed a small-molecule
cell microarray format that is compatible with existing chemical
libraries, in which compounds are typically stored as frozen
solutions in dimethyl sulfoxide. We have performed proof-of-
principle experiments to evaluate this screening format.
Materials and Methods
Reagent Preparation. In a 2-ml microfuge tube, 100 mg of PLGA
(lactideglycolide ratio, 50:50; inherent viscosity, 0.5–0.68; cat-
alog no. 48300-025, Polysciences) was added to 1 ml of methyl
salicylate (catalog no. M-2047, Sigma). The tube was vortex
mixed (minivortex at setting 10; Sigma) for 30min, aliquoted into
1-ml tubes, and stored at 20°C. All compounds were from
Sigma, Calbiochem, and the National Cancer Institute and were
dissolved in microfuge tubes at a concentration of 80 mM in
DMSO (catalog no. D-5879, Sigma). Compounds were further
diluted in DMSO and stored at 20°C. To prepare fibronectin
(catalog no. 354008, BD Biosciences), 1 ml of sterile H2O was
added to a vial containing 1 mg of fibronectin, and the solution
was incubated at room temperature (RT) for 45 min, aliquoted,
and stored at 20°C.
Microarray Printing.Amicroarraying robot (Pixsys 5500, Genomic
Solutions, Ann Arbor, MI) with SMP4 and SMP10 pins (Arrayit
SMP4 or SMP10, Telechem, Sunnyvale, CA) was used to deposit
reagent on Ni-chelated glass slides (catalog no. MNC00010,
Xenopore, Hawthorne, NJ). Ni-chelated slides were used be-
cause the surface allowed for the printing of small, well-formed
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polymer spots and mammalian cell attachment. Before printing,
20 l of printing solution was loaded into a round-bottom,
polypropylene 384-well plate and centrifuged with a Beckman
GS-6R centrifuge with a GH3.8A horizontal rotor at 1,000 rpm
for 30 sec. All printing was performed at 23°C with 55%
humidity. The small-molecule microarray spots were built by
layering different solutions in the same position. Polymer (100
mgml1 PLGA in methyl salicylate) was printed with an SMP4
pin by using a pins-down slide time of 50 msec. After a 10-min
drying time, an SMP10 pin was used to deposit one to five cycles
of compoundDMSO (20 nl total) by using a pins-down slide
time of 1,000 msec. Each cycle was separated by at least 8 min
of drying time to allow for DMSO evaporation. Finally, spots
were topped by using an SMP4 pin to deposit methyl salicylate
with a pins-down slide time of 300 msec. Once printed, arrays
were desiccated for 30 min at RT and stored at 4°C or used
immediately. Spot sizes were 200 m. The spot-to-center
distances featured in each figure is as follows: Fig. 1, 500m; Fig.
2,3 mm; Fig. 3, 4 mm; and Fig. 4, 1.12 mm for the initial screen
and 4.5 mm for the retest.
Small-Molecule Microarray Assay. If previously printed and stored,
slides containing arrays were desiccated at RT for 30 min then
placed in a Petri dish at RT. One milliliter of fibronectin (diluted
1:30 in DMEM from frozen aliquots) was deposited on the array-
containing slides. After 1 h of incubation at RT, slides were rinsed
in sterile H2O and placed in a 100  100  10-mm, square
tissue-culture dish. Actively growing cells in 25 ml of culture
medium (A549 cells, DMEM with 10% FBS50 unitsml1 peni-
cillin50 gml1 streptomycin; HeLa cells, DMEM with 10%
inactivated FCS50 unitsml1 penicillin50 gml1 streptomycin)
were seeded on arrays and incubated at 37°C in 5% CO2. When
performing longer assays, fewer cells were seeded to achieve similar
final cell densities. For 14-h incubation, we seeded eight million
cells; for 38-h incubations, we seeded fourmillion cells; and for 62-h
incubations, we seeded two million cells. After growth for the
specified amount of time, slides were fixed by using 3.7% parafor-
maldehyde and 4% sucrose in PBS for 20 min at RT.
siRNA Transfection. We seeded two million cells in 5 ml of medium
in a 10-cm, round tissue-culture dish for 14 h in culturemedium.We
rinsed the cells twice with 5 ml of Optimem (Invitrogen). After the
final aspiration, we added 4ml of Optimem to each dish and set the
dish in an incubator during the preparation of the siRNA trans-
fection reagents. The cells were transfected with siRNA [BCL2,
M-003307-00-05; BRCA1, P-002111-01-05; EGFR, M-003114-00-
05; MDM2, M-003279-00-05; p53, M-003557-00-05; PTEN,
M-003023-00-05; tuberous sclerosis complex gene 2 (TSC2),
M-003029-00-05; Dharmacon] by using the Effectene transfection
kit (catalog no. 301427, Qiagen, Valencia, CA). We mixed 300 l
of EC buffer with 25 l of a 20 M siRNA solution. After the
addition of 16l of enhancer, the solution was vortexmixed on high
for 1 sec. After a 5 min of incubation at RT, 40 l of Effectene
reagent was added. The solutionwas vortexed for 10 sec on high and
incubated at RT for 10 min. Optimem (700 l) was added, mixed,
and placed (total preparation, 1 ml) into a 10-cm dish of cells.
Cells were incubated at 37°C in 5%CO2 for 24 h and removed with
trypsinEDTA for use on microarrays.
Synthetic Lethal Screen. Arrays were seeded with four million cells
(previously transfected with siRNA reagents as described above) in
25 ml of cell culture media and incubated for 38 h. At the time of
microarray seeding, in a parallel experiment, onemillion cells of the
same type in 4 ml of medium were seeded in 6-cm, round tissue-
culture dishes and incubated for the same 38 h. After incubation,
cells on arrays were fixed and stained; cells in 6-cm dishes were
Fig. 1. Robot-generated arrays of biodegradable polymer. (a) An array of 441 spots was printed on a slide. The center spot was loaded with 50 pmol of PAO,
and all other spots were loaded with DMSO. In the photographs, nuclei are blue (Hoechst stain) and filamentous actin is green (phalloidin–FITC stain). (b) Pictures
of an array of spots loaded with podophyllotoxin (Left) and PAO (Right) showing a dose–response effect on A549 cells. (c) Quantitation of cell density from the
images in b for each concentration of drug at different distances from the spot (the units of the vertical axis are cells per unit of area for all graphs in this figure).
(d) Replicates of the arrays used in c assayed with HeLa cells. (e) Replicate arrays of b that were stored at 4°C for 48 h and then assayed by using A549 cells.

















prepared for Western blot analysis of protein levels. The complete
experiment required the analysis of 78 slides. By using parameters
defined below in the image analysis section, it took 7 min to
acquire the images for each slide (9 h total). We measured cell
density at six different distances from the center of the 528 different
spots on each slide. The analysis of one slide of images took 40
min (52 h total) by using a standard Pentium 4, 2-Ghz processor
with 2 gigabytes of random access memory.
Western Blots. After 38 h, cells in 6-cm dishes were lysed and
Western blots performed (40). Equal protein was loaded in each
lane, normalized by using a BSA standard. Primary mouse mono-
clonal antibodies were used at the following concentrations: anti-
p53, 1:500 (Ab-6, Oncogene Science); anti-PTEN, 1:1,000 (MS-
1250-P0, Lab VisionNeomarkers, Fremont, CA); anti-BCL2,
1:500 (sc-7382, Santa Cruz Biotechnology); anti-MDM2, 1:1,000
[sc-965 (SMP14), Santa Cruz Biotechnology]. Primary rabbit poly-
clonal antibodies were used at the following concentrations: anti-
BRCA1, 1:100 (sc-642, Santa Cruz Biotechnology); anti-TSC2,
1:500 (Santa Cruz Biotechnology); anti-EGFR, 1:1,000 (sc-03,
SantaCruzBiotechnology). Secondary antibodieswere horseradish
peroxidase-labeled anti-mouse or anti-rabbit antibodies produced
in donkeys (Jackson ImmunoResearch) and were used at a 1:5,000
dilution.
Immunofluorescence. All cells on arrays in Figs. 1, 3, and 4 were
stained with phalloidin–FITC (F432, Molecular Probes) and
Hoechst 33342 (H3570, Molecular Probes). After fixation, cells
were permeabilized with 0.2% Triton X-100 for 20 min and
placed in a humidity chamber with cell side up. Ten units of
phalloidin in 1 ml of PBS was deposited on each slide surface and
incubated at RT for 40 min. Cells were dipped in PBS, placed in
a humidity chamber and incubated with 1 ml of Hoechst 33342
(1:10,000 dilution in PBS) for 30 min. For Fig. 2, cells were fixed
as above, permeabilized with 0.2% Triton X-100 for 40 min and
probed with primary and secondary antibodies. The primary
rabbit polyclonal antibody used was anti-pS6 (ser2404, Cell
Signaling); 500 l of antibody per slide was used at a dilution of
1:500. The secondary antibody used was anti-rabbit cy3 (The
Jackson Laboratory) at a dilution of 1:1,000. After completion
of secondary antibody probe, slides were stained with Hoechst
33342.
Image Capture and Analysis. We captured images of all slides by
using both light and fluorescence microscopy with a Zeiss Axiovert
200 at 50 magnification and custom software designed on the
KS400 software platform.Unless otherwisementioned, wemeasured
the number of Hoechst-stained nuclei divided by area in a region
of interest (ROI). We used a finite set of circular regions centered
on a spot with radii increasing in increments of 150 m to define
ROIs. All ROIs were labeled for the radius of their outer boundary,
Fig. 2. Extended release of rapamycin. (a) These arrays are stained with
Hoechst 33342 and a cy3-anti-pS6 antibody [a downstream effector of mTOR
(cells affected by rapamycin show a lack of S6 phosphorylation)]. For each spot,
the largest radius of effect was determined by measuring pS6 per unit of area.
Regions with average pS6 levels below a threshold were considered affected.
Each line in the graph represents the concentration of rapamycin in relation
to the radius of effect for each storage condition. (b) The quantitation of pS6
intensity and the number of cells per unit of area at 50-m intervals from the
center of a spot loaded with 7.5M rapamycin. The level of pS6 increases with
increasing distance from the center of the spot, suggesting that a concentra-
tion gradient has been established. Consistent with the known effects of
rapamycin, the spots have a mild antiproliferative effect on cells in a dose-
dependent manner.
Fig. 3. Evaluation of 12 compounds in the microarray format. (a) The graph
compares a calcein assay performed in microtiter plates with a cell-density
assay performed on a microarray by using verrucarin A [502.5 atomic mass
units (amu)] in A549 cells. (b) Each graph represents the effect of a different
compound known to be active against A549 cells assayed in the microarray
format (n 3). Each graph shows five different concentrations of compound
and a ‘‘no compound’’ control (far right). (c) Images of cells affected by
different compounds. Nuclei are blue (Hoechst stain), and filamentous actin is
green (phalloidin–FITC stain). We presume that the distance over which
compounds act is determined by potency; intrinsic activity; partitioning of
each compound between the slide surface, cell surfaces, and the medium; and
the rate of diffusion of each compound out of the polymer, through the
medium, and along the slide surface.
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and all ROIs, except the first, were shaped like a ring. The smallest
ROI measured for each spot was a circle centered on the spot with
a radius of 150 m. The next largest ROI (radius of 300 m) was
shaped like a ring and was calculated by subtracting a circle with a
radius of 150 m from a circle with a radius of 300 m.We divided
the number of nuclei counted in eachROIby the area (m2) of each
ROI to get the number of cells per area (CPA). For each slide, we
averaged all of the spots loaded with DMSO (negative controls) to
get a normal CPA for each ROI. We divided all measurements of
CPA taken from each ROI of an experimental spot with the
average normal CPA measurements to get a percentage of CPA.
All data analysis was performed on values of percentCPA.Weused
a two-sample, heteroskedastic t test to compare percent CPA values
generated by compounds affecting cells transfected with siRNA
versus without siRNA. The values of CPA reported in Figs. 1 and
3 are the average of the percent CPA for all replicates and the error
bars are the standard deviation. In Fig. 4, error bars are standard
error of the mean (SDn). Fig. 2 was analyzed by using the same
ROI format, but instead of measuring the number of nuclei, we
measured the total cy3-pS6 signal for each ROI and divided that by
the area of each ROI. This calculation gave the average signal per
unit area (SPA). These values were normalized to spots with no
activity and a percentage of SPA was calculated. A value of 100%
equals pS6 in a normal cell population and 0%equals no detectable
pS6.We set 80%as a threshold such that anROIwith a value below
80%was considered affected. For each concentration of rapamycin,
we reported the outer radius of the largest ROI that had a percent
SPA (an average value of three replicates) below our threshold. All
percent SPA of smaller ROIs of an affected spot were below the
threshold but not reported.
Microtiter Plate Assay. Assays were performed according to the
methods described in ref. 41. Four or eight thousand A549 cells
were seeded per well for 14 h before compound was added. After
the addition of compound to each well, the cells were incubated
for 62, 38, or 14 h, respectively, and then assayed by using a
calcein acetoxymethyl ester viability assay (Molecular Probes).
Results
We evaluated numerous polymer matrices, solvents, and array-
ing conditions to create a small-molecule-compatible, cell-
microarray screening system. In the optimal system, we depos-
ited picomoles of each compound on a solid surface encased in
a biodegradable polymer, providing sustained release. We grew
cells on the surface of the microarray and imaged the resulting
adherent cells to identify cellular responses specific to the
compound present in each spot.
We discovered that PLGA, a biodegradable polymer, is capable
of releasing small molecules in a controlled fashion in a microarray
format. This polymer dissolves in numerous liquid solvents at RT
to form a solution with a viscosity and volatility that is compatible
with printing by using a miniaturized arraying pin. We deposited at
each position on a glass microscope slide 1 nl of PLGA solution
that dried to form an200-mdiameter spot. These polymer spots
typically formed doughnut-like shapes when they dried, with a
thicker edge and a thinner center. Polymer spots were printed in the
desired array configuration and, once dried, loaded with20 nl of
a compound of interest dissolved in DMSO. To load a feature, we
deposited a compound solution on top of each polymer spot by
using an arraying pin. Subsequently, we spotted1 nl of the solvent
methyl salicylate onto each spot, allowing for the mixing of the
compound into the polymeric matrix. This method allows us (i) to
print an array of control polymer spots on a slide lacking test
compounds (i.e., treated only with PLGA, DMSO, and methyl
salicylate), (ii) to print a library of compounds previously dissolved
in DMSO, and (iii) to arrange the test compounds and spots in any
desired configuration.
As an initial test of the utility of this system, we printed an array
of 441 spots and loaded all spots except the center spot withDMSO.
The center spot was loaded instead with phenylarsine oxide (PAO),
a cytotoxic compound that inhibits protein–tyrosine phosphatases
and bis-thiol-containing proteins and is cytotoxic to A549 human
lung carcinoma cells (41–45). Subsequently, we seeded A549 cells
onto this microarray and incubated the cells on the array for 38 h.
The cells grew to confluence throughout the array except around
the area containing the PAO-loaded polymer. Longer or shorter
incubation times did not result in a significantly larger or smaller
ring of effect (data not shown). These results suggest that the PAO
was released from the polymer spot and affected the cells growing
within several hundred micrometers of this spot (Fig. 1).
As compounds were released from the polymer matrix, they
diffused into surrounding culture medium; therefore, we expected
to see a decrease in compound concentration and the correspond-
ing cellular effect with an increase in distance from the spot. We
measured cell density (i.e., CPA) at different distances from each
spot center and found that all spots loaded with DMSO had
Fig. 4. Synthetic lethal screen of 70 compounds. We used siRNAs in either
A549 or HeLa cells to knock down one of seven target genes and then seeded
each set of knocked-down cells on identical microarrays loaded with 70
different compounds. (a) To confirm that each siRNA was effective, we per-
formed Western blots on small aliquots of cells that were simultaneously
seeded on the microarrays. The right lane of the blots was loaded with lysate
from cells transfected with siRNA for a target gene, and the left lane was
loaded with lysate from cells treated with the same reagents without the
siRNA. All gels were loaded with samples normalized for total protein. (b) We
found four compound–siRNA pairs in which there was a significant difference
in activity in the microarray format. Student’s t tests were performed on cell
density measurements taken at each distance from the center of the spots, and
significant changes in cell density are highlighted in yellow. (c) We confirmed
the macbecin IITSC2 synthetic lethal effect by using a calcein acetoxymethyl
ester viability assay in microtiter plates.

















distance-independent densities similar to normal cell densities,
0.7 cells per unit of area (Fig. 5, which is published as supporting
information on the PNAS web site). The area occupied by the spot
loaded with PAO had the lowest cellular density, 0.04 cells per
unit of area. We observed that PAO has an IC50 of 2 M in typical
384-well-plate-based experiments (data not shown). When testing
in the microarray format, we found that spotting 200 pmol of
PAO in aDMSOPLGA solution gave a half-maximal effect on the
spot. Thus, we estimate that these conditions produce a localized
concentration of 2 M PAO around such a spot. In addition,
cellular densities increased with increasing distance from the spot
center (Fig. 1). This finding suggests that a concentration gradient
of PAOwas established around the spot and the cells were affected
in a dosage-dependent fashion at increasing distances from the
PAO-loaded spot.
Next, we tested the effect of loading different amounts of a
compound onto a small-molecule cell microarray. We created a
polymer microarray containing a dilution series of either podo-
phyllotoxin (PTX) or PAO and cultured A549 cells on it (Fig. 1).
Similar to previous experiments, we found that spots loaded with
PTX or PAO affected cells in a dose-dependent manner. In every
case, the cell density was lowest on the spot with one of these
cytotoxic compounds and increased with increasing distance. Spots
loaded with a larger amount of compound tended to have a more
profound and widespread effect. For example, spots loaded with
400 pmol of PAO affected a larger area and resulted in lower cell
densities at similar distances when comparedwith spots loadedwith
200 pmol of PAO (Figs. 1 b and c). Both PAO and PTX are
cytotoxic but have different potencies, maximal activities, and
mechanisms of action. PTX is more potent (i.e., active at lower
concentrations) but has a weaker effect on cell density and cell
viability than PAO. Of the spots loaded with PAO, only spots
loaded with 400 or 200 pmol exhibited a visible effect on cell
density. Moreover, the effect of PAO on these cells was local and
striking. In contrast, spots loaded with all amounts of PTX reduced
cell density. Although not as striking as the PAO-loaded spots, at
similar concentrations, the PTX-loaded spots affected the cell
density of larger surface areas. The results suggest that compound-
specific effects occur in a dosage-dependant fashion on the
microarrays.
By using plate-based methods, compounds show different po-
tencies in different cell types (41).We tested the small-molecule cell
microarray method on multiple cell types by comparing the effects
of PTX and PAO in HeLa and A549 cells. Both compounds were
more potent in HeLa cells compared with A549 cells, demonstrat-
ing that thismicroarray format is not limited to the use ofA549 cells
and that the activity in the small-molecule microarray system can
depend on cell type (Fig. 1). In addition to A549 and HeLa cells,
we have successfully tested the microarrays by using five other cell
lines: BJ, BJELR, MEF, 293T, and DU145 (data not shown).
To determine the stability of a printed, PLGA-impregnated,
small-molecule microarray, we took replicate slides containing
microarrays loaded with a dilution-series of PTX and PAO and
stored them at 4°C for 48 h. After storage, the slides were assayed
as before by measuring the density of A549 cells throughout the
slide (Fig. 1e) and compared with the results obtained on a freshly
printed slide. The potencies of PTX and PAO appeared similar in
the stored array and the freshly printed array, demonstrating that
the arrays can be stored for at least 48 h with little reduction in
effectiveness.
We tested arrays loaded with PAO and PTX assayed for time
periods upwards of 10 days to evaluate compound diffusion. As
expected, these longer preincubation times produce similar or
slightly reduced phenotypes and ring sizes when compared with
72-h preincubation times (data not shown). This result indicates that
the compound is being depleted from the spots creating a stable
concentration gradient that will not affect an increasing area over
time.
We sought to determine whether we could detect cellular phe-
notypes other thandeath in themicroarray format. Toward this end,
we tested the effects of the natural product rapamycin on the
phosphorylation status of S6 in A549 cells. Rapamycin inhibits
the mammalian target of rapamycin (mTOR) pathway, causing the
dephosphorylation of its downstream effector, the ribosomal S6
protein. To evaluate the release profile of rapamycin from PLGA
spots over extended periods of time, we performed the following
experiment. We seeded A549 cells on four identical arrays loaded
with rapamycin and incubated the arrays at 37°C with 5% CO2 for
24, 48, 72, and 168 h. After this initial ‘‘presoak’’ period, we stripped
the cells from the arrays, reseeded them with fresh A549 cells, and
quantitated the pS6 levels 48 h after the second seeding. The
purpose of the presoaking period was to enable the normal pro-
cesses of biodegradation and bioerosion of the PGLA polymer that
occur in the presence of cells. If most of the rapamycin was released
from the PLGA spots as an initial bolus, most presoaked arrays
should have a dramatic reduction in pS6 when compared with a
nonpresoaked array. If the rapamycin was released slowly, presoak-
ing an array should reduce the amount of pS6 proportional to length
of presoaking time.We classified affected areas as having80% of
the mean pS6 signal when compared with the mean pS6 of normal
A549 cells. By using this threshold, we calculated the size of the ring
of affected area for each spot on the array (Fig. 2a).
For each array, we found that the size of the area of affected cells
increased with increasing amounts of deposited rapamycin. In
general, all rapamycin-containing spots were still active after pre-
soaking; they have smaller radii of effect with lower rapamycin
concentrations, suggesting that, as the time of contact with cells
increases, the rate of release might decrease. One possible expla-
nation is that the release of compound from the polymer obeys
first-order kinetics; i.e., the release of compound is proportional to
the amount of compound present the polymer matrix.
To control for possible degradation of compounds or polymer
unrelated to soaking with cells, we incubated an array at 4°C for
168 h. This array was somewhat less effective than the freshly
printed array but more effective than the array that had been
incubated with cells for the same 168-h time period.
The spots loaded with the smallest amount of rapamycin were
still active under all presoaking conditions, demonstrating that a
minimum level of release sufficient to affect pS6 levels is
maintained. These results indicate that PLGA provides sus-
tained release of compounds and demonstrates the usefulness of
themethod in assays up to at least 72 h. (Fig. 6, which is published
as supporting information on the PNAS web site).
The biodegradable polymers used for clinical drug delivery are
optimized around a single compound and rate of release. We
required a polymer that allowed for the release of many different
compounds, independent of their physical properties. To test the
breadth of utility of PLGA, we assayed a set of 12 compounds
known to be lethal toA549 cells and ranging inmolecularmass from
167 to 1,255 atomic mass units (41). A dilution series of each
compound was deposited in the microarray format, and cell density
wasmeasured. These 12 compounds had somediscernable effect on
the density of A549 cells, demonstrating that compounds with a
range of physical properties can be used in this system (Fig. 3). An
attempt was made to assess whether the potencies of these com-
pounds correlated with their physical properties. Although each
compound had a specific inhibitory effect on A549 cells, the
compounds’ potencies did not correlate with any molecular de-
scriptors we tested (Fig. 3).
We performed a small-scale screen to test the ease of by using
small-molecule cell microarrays in a screening process. Toward this
end, we performed a synthetic lethal screen of known compounds
against a set of cancer-related target genes. Our goal was to find
compounds that are not generally lethal to cells but display in-
creased or decreased activity in the presence or absence of specific
cancer-related genes. Such compounds may be candidate thera-
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peutic agents, or they may be useful probes of the functions of the
tested cancer-related genes (46–49).
For this synthetic lethal screen, we used two cell types (A549 and
HeLa), each separately transfected with one of seven different
siRNAs that targeted for destruction mRNAs encoding p53,
PTEN, MDM2, EGFR, TSC2, BCL2, and BRCA1. Thus, we had
16 cell conditions under which to test each compound (no siRNA
plus seven siRNAs in two cell types). We assayed a set of 70 known
biologically active compounds that we selected from Sigma, Cal-
biochem, and the National Cancer Institute. Each compound was
tested in triplicate at three concentrations in each cell condition for
its effect on cellular density. This small pilot experiment involved
the collection of 50,000 data points.
Knockdown of mRNAs by using siRNAs is transient and can be
of variable effectiveness; thus, it is important tomeasure directly the
change in the concentration of the target protein in siRNA-
mediated knockdown experiments. When we seeded each cell
sample on the microarrays, we also grew up a small amount of the
cell sample in parallel for Western blot analysis of target protein
level (Fig. 4).
Compounds that caused a significant change (P  0.05) in cell
density under a specific set of conditions were considered putative
hits. The putative hits were retested with more replicates under the
same conditions to confirm their effects. We discovered that the
effectiveness of three of the 70 compounds (cisplatin, macbecin II,
and nocodazole) was altered in some of the siRNA-transfected cells
(Fig. 4). In HeLa cells with reduced levels of p53, macbecin II, and
cisplatin had altered effects. In HeLa cells with reduced levels of
TSC2 or PTEN, macbecin II and nocodazole, respectively, had
reduced effects. Thus, of 980 compound-siRNA cell-type combi-
nations tested, we found four in which knockdown of a specific
mRNA altered the sensitivity of tumor cells to a specific compound
in the microarray format. We retested these potential synthetic
lethal effects in a conventional calcein acetoxymethyl ester viability
assay in 384-well plate format and found that one was confirmed:
Reduction of TSC2 caused a detectable level of resistance to
macbecin II (Fig. 4c).
Discussion
Macbecin II is a DNA antimetabolite that induces breaks in
double-stranded DNA, possibly by means of p53-mediated apopto-
sis (50). Reduction in TSC2 has been shown to activate mTOR-
mediated cellular hyperplasia and hypertrophy (51). Our results
show that cells with reduced levels of TSC2 are less susceptible to
macbecin II. In some systems, loss of mTOR activity is associated
with p53-dependent apoptosis (52). Our results support this finding
by suggesting that enhancement of cellular growth through loss of
TSC2 may help overcome the apoptotic effects of DNA damage.
Furthermore, TSC2 knockdown affected the activity ofmacbecin II
and not cisplatin, further implicating distinct p53-related cellular
responses.
Although the small-molecule cell microarray method shows
promise, there are technical limitations that require attention.
Currently, printing densities are limited to prevent one spot from
affecting cells on another nearby spot. We have experimented with
decreasing the effect of compound crosscontamination by using
simple methods, such as overhead stirring (data not shown). In
addition, it would be advantageous to have a polymer that could be
induced to release compounds at a specified time, which would add
a new level of elegance, whereby one could stabilize cellular states,
such cell cycle progression, before release of the compounds.
The microarray format uses a small amount of each compound
in each test and requires fewer cells than plate-based experiments.
Small-molecule cell microarrays may be advantageous when testing
a rare and precious natural product. The method we have devel-
oped for making these microarrays is compatible with most large
chemical libraries, which are typically dissolved in DMSO.
In summary, we have reported the construction of a cell mi-
croarray that enables the screening of small-molecule libraries in
mammalian cells. Thesewell-less arrays are compatiblewith current
cell-based assays and high-resolution imaging techniques. This
microarray is a high-throughput, high-content method of screening
small molecules that uses small amounts of compound, few cells,
imaging-based readouts, and the potential to screen many com-
pounds with minimal automation. This method will be useful to
those performing small-molecule screens to discover new chemical
tools and potential therapeutic agents.
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